Related references
Note: Only part of the references are listed.2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD
Julio Alejandro Lamprea-Montealegre et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation
Stephen Zewinger et al.
NATURE IMMUNOLOGY (2020)
Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2020)
Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA JACC State-of-the-Art Review
Julius L. Katzmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Hossein Taheri et al.
CARDIOLOGY (2020)
Comparison of interteukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2020)
Metabolic risk profile in kidney transplant candidates and recipients
Giovanni Piotti et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
HDL-Targeted Therapies During Myocardial Infarction
Andrei C. Sposito et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Jordan Fulcher et al.
LANCET (2019)
IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD
Adriana M. Hung et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
David M. Charytan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis
Zhimiao Wang et al.
LIPIDS IN HEALTH AND DISEASE (2019)
Proprotein convertase subtilisin/kexin type 9 in kidney disease
David Schmit et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease A Mendelian Randomization Study
Frida Emanuelsson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes A Randomized Clinical Trial
Ian H. de Boer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Chronic Kidney Disease and Coronary Artery Disease
Mark J. Sarnak et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean-Claude Tardif et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study
Richard L. Amdur et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
Michael B. Boffa et al.
NATURE REVIEWS CARDIOLOGY (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD
Archna Bajaj et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
Robert S. Rosenson et al.
NATURE REVIEWS CARDIOLOGY (2018)
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
Shipra Agrawal et al.
NATURE REVIEWS NEPHROLOGY (2018)
HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study
Matthew B. Lanktree et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis
Marit Westerterp et al.
CIRCULATION (2018)
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
Aruna D. Pradhan et al.
CIRCULATION (2018)
The role of lipoprotein (a) in chronic kidney disease
Jemma C. Hopewell et al.
JOURNAL OF LIPID RESEARCH (2018)
Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke
Michael V. Holmes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
Paul M. Ridker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
HDL in CKD-The Devil Is in the Detail
Florian Kronenberg
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease
Peter P. Toth et al.
KIDNEY INTERNATIONAL (2018)
Alteration of HDL Protein Composition with Hemodialysis Initiation
Ke Wang et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events
Shahzad Chindhy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
Aruna D. Pradhan et al.
AMERICAN HEART JOURNAL (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects
Maria Giovanna Lupo et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2018)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein (a): a historical appraisal
Karam M. Kostner et al.
JOURNAL OF LIPID RESEARCH (2017)
Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease
Stephen Zewinger et al.
EUROPEAN HEART JOURNAL (2017)
Lipoprotein(a): the revenant
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2017)
Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD
Anjali Ganda et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2017)
Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism
Hua Chen et al.
JOURNAL OF PROTEOME RESEARCH (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms
G. Kees Hovingh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Kidney function is associated with an altered protein composition of high-density lipoprotein
Katya B. Rubinow et al.
KIDNEY INTERNATIONAL (2017)
Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease
Jair Munoz Mendoza et al.
KIDNEY INTERNATIONAL (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
F. E. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study
Stephen Zewinger et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease Findings From the CRIC Study (Chronic Renal Insufficiency Cohort)
Archna Bajaj et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Current therapies for lowering lipoprotein (a)
Julian C. van Capelleveen et al.
JOURNAL OF LIPID RESEARCH (2016)
HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients
Wijtske Annema et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis
Xiaole Su et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization
Eberhard Roeseler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among US Veterans
Benjamin Bowe et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli et al.
EUROPEAN HEART JOURNAL (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein apheresis to treat elevated lipoprotein (a)
Elisa Waldmann et al.
JOURNAL OF LIPID RESEARCH (2016)
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
Borge G. Nordestgaard et al.
JOURNAL OF LIPID RESEARCH (2016)
Carbamylated Low-Density Lipoproteins Induce a Prothrombotic State Via LOX-1 Impact on Arterial Thrombus Formation In Vivo
Erik W. Holy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Impaired postprandial lipemic response in chronic kidney disease
Jeffrey M. Saland et al.
KIDNEY INTERNATIONAL (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study
Barbara Kollerits et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Frederick F. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
William G. Herrington et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Carbamylated Low-Density Lipoprotein (cLDL)-Mediated Induction of Autophagy and Its Role in Endothelial Cell Injury
Chhanda Bose et al.
PLOS ONE (2016)
Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function
Jia Teng Sun et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2016)
Impact of the Triglycerides to High-Density Lipoprotein Cholesterol Ratio on the Incidence and Progression of CKD: A Longitudinal Study in a Large Japanese Population
Kazuhiko Tsuruya et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Intestinal Cholesterol Absorption, Treatment With Atorvastatin, and Cardiovascular Risk in Hemodialysis Patients
Guenther Silbernagel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Dialysis Modalities and HDL Composition and Function
Michael Holzer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis
Chantal Kopecky et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease
Ana Reis et al.
JOURNAL OF LIPID RESEARCH (2015)
Restoration of Renal Function Does Not Correct Impairment of Uremic HDL Properties
Chantal Kopecky et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients
Guenther Silbernagel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials
Sripal Bangalore et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Lower Apo A-I and Lower HDL-C Levels Are Associated With Higher Intermediate CD14++CD16+ Monocyte Counts That Predict Cardiovascular Events in Chronic Kidney Disease
Kyrill S. Rogacev et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Relation of Serum Lipids and Lipoproteins with Progression of CKD: The CRIC Study
Mahboob Rahman et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Carbamylated low-density lipoprotein induces endothelial dysfunction
Thimoteus Speer et al.
EUROPEAN HEART JOURNAL (2014)
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa for Lowering Very high triglyceridEs (EVOLVE) trial
John J. P. Kastelein et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
Robert S. Rosenson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
HDL Cholesterol Is Not Associated with Lower Mortality in Patients with Kidney Dysfunction
Stephen Zewinger et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
HDL in Children with CKD Promotes Endothelial Dysfunction and an Abnormal Vascular Phenotype
Rukshana Shroff et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Effects of Lowering LDL Cholesterol on Progression of Kidney Disease
Richard Haynes et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
Alberto Ortiz et al.
LANCET (2014)
Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients
Hamid Moradi et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
Anand Rohatgi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia
Howard S. Weintraub
POSTGRADUATE MEDICINE (2014)
Regulation of lipoprotein lipase by AngptI4
Wieneke Dijk et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2014)
Defining the Natural History of Uremic Cardiomyopathy in Chronic Kidney Disease The Role of Cardiovascular Magnetic Resonance
Nicola C. Edwards et al.
JACC-CARDIOVASCULAR IMAGING (2014)
Arterial disease in chronic kidney disease
William E. Moody et al.
HEART (2013)
Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2
Thimoteus Speer et al.
IMMUNITY (2013)
Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets
Mikael Larsson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Association between LDL-C and Risk of Myocardial Infarction in CKD
Marcello Tonelli et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Ron T. Gansevoort et al.
LANCET (2013)
Common variants associated with plasma triglycerides and risk for coronary artery disease
Ron Do et al.
NATURE GENETICS (2013)
CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation
Frederick J. Sheedy et al.
NATURE IMMUNOLOGY (2013)
Uraemic dyslipidaemia revisited: role of high-density lipoprotein
Thimoteus Speer et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Activation and regulation of the inflammasomes
Eicke Latz et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
Christie M. Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease A Systematic Review and Meta-analysis
Suetonia C. Palmer et al.
ANNALS OF INTERNAL MEDICINE (2012)
Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
Suguru Yamamoto et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Serum Amyloid A in Uremic HDL Promotes Inflammation
Thomas Weichhart et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Everyone under statin?
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2012)
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Benjamin F. Voight et al.
LANCET (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
B. Mihaylova et al.
LANCET (2012)
Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis
Melissa Y. Wei et al.
CURRENT ATHEROSCLEROSIS REPORTS (2011)
Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease
Esther M. M. Ooi et al.
JOURNAL OF LIPID RESEARCH (2011)
Uremia Alters HDL Composition and Function
Michael Holzer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
Amit V. Khera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures
W. Greg Miller et al.
CLINICAL CHEMISTRY (2010)
Hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic Kidney Disease
Varun Chawla et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Arterial stiffness in chronic kidney disease: causes and consequences
Colin D. Chue et al.
HEART (2010)
Chronic Uremia Stimulates LDL Carbamylation and Atherosclerosis
Eugene O. Apostolov et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell et al.
NATURE (2010)
Atherosclerosis in CKD: differences from the general population
Tilman B. Drueeke et al.
NATURE REVIEWS NEPHROLOGY (2010)
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Kiran Musunuru et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients
Kamal S. Hassan et al.
RENAL FAILURE (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Association of LDL Cholesterol and Inflammation With Cardiovascular Events and Mortality in Hemodialysis Patients With Type 2 Diabetes Mellitus
Vera Krane et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Fibrate therapy and renal function
Domenic A. Sica
CURRENT ATHEROSCLEROSIS REPORTS (2009)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin: cholesterol acyltransferase in end-stage renal disease (ESRD)
Madeleine V. Pahl et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Low-density lipoprotein clearance in patients with chronic renal failure
Helena Kastarinen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Bengt C. Fellstroem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease
James Shepherd et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
Michael Miller et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study
My Svensson et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Toni I. Pollin et al.
SCIENCE (2008)
Protein carbamylation links inflammation, smoking, uremia and atherogenesis
Zeneng Wang et al.
NATURE MEDICINE (2007)
Association between serum lipids and survival in hemodialysis patients and impact of race
Ryan D. Kilpatrick et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Review of the effects of omega-3 supplementation in dialysis patients
Allon Friedman et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
ND Vaziri
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis
K Ikewaki et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin:: The ALERT extension study
H Holdaas et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Carbamylated low-density lipoprotein induces death of endothelial cells: A link to atherosclerosis in patients with kidney disease
E Ok et al.
KIDNEY INTERNATIONAL (2005)
Seasonal variation in serum cholesterol levels - Treatment implications and possible mechanisms
IS Ockene et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Association between cholesterol level and mortality in - Role of inflammation dialysis patients and malnutrition
YM Liu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Effect of pravastatin on cardiovascular events in people with chronic kidney disease
M Tonelli et al.
CIRCULATION (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Fibrate-induced increase in blood urea and creatinine
J Lipscombe et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2001)
Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial
SJ Robins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
